LONDON, ONTARIO -- (MARKET WIRE) -- December 14, 2006 -- Stellar Pharmaceuticals Inc. ("Stellar" or "the Company") (TSX VENTURE: SLX)(OTCBB: SLXCF) today announced that Watson Pharmaceuticals, Inc. ("Watson") (NYSE: WPI) has acquired the exclusive development and commercialization rights for Uracyst®, Stellar's novel agent for the treatment of interstitial cystitis.
